Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C102981
http://purl.obolibrary.org/obo/NCIT_C102981
|
|---|---|
| Preferred Name | Iodine I 131 Rituximab |
| Definitions |
A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 rituximab binds to the CD20 antigen thereby delivering cytotoxic iodine I 131 specifically to cancer cells expressing CD20. The CD20 antigen, a hydrophobic transmembrane protein, is expressed on normal pre-B and mature B lymphocytes.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 rituximab binds to the CD20 antigen thereby delivering cytotoxic iodine I 131 specifically to cancer cells expressing CD20. The CD20 antigen, a hydrophobic transmembrane protein, is expressed on normal pre-B and mature B lymphocytes. |
|---|---|
| prefLabel | Iodine I 131 Rituximab
|
| label | Iodine I 131 Rituximab
|
| PDQ_Closed_Trial_Search_ID | 739942
|
| code | C102981
|
| prefixIRI | NCIT:C102981
|
| in_subset | |
| Preferred_Name | Iodine I 131 Rituximab
|
| FDA_UNII_Code | K2I4B6I9L1
|
| Contributing_Source | FDA
|
| Maps_To | Iodine I 131 Rituximab
|
| NCI_Drug_Dictionary_ID | 739942
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 739942
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1676077
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |